BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the business.
In a report released on March 14, Jessica Fye from J.P. Morgan maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...
In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback